Pipeline: Vascular Biogenics’ pipeline is built upon two proprietary platform technologies that have promising potential for long term growth if the initial candidates prove successful.
The company’s Vascular Targeting System delivers synthetically derived gene therapy which can be used to either destroy or promote angiogenic blood vessels. Angiogenic blood vessels form when angiogenic growth factors activate receptors on endothelial cells to trigger a release of enzymes that allow the endothelial cells to escape and form connections with neighboring vessels. This process is natural in the body and is a key process supporting tumor metastasis. The flexibility to either express or suppress development of angiogenic blood vessels opens up a lot of potential uses for technology, from starving tumor cells (i.e. as it is in the current study) to delivering growth factors for other conditions.
The pipeline for the Vascular Targeting System boasts three late stage trials of VB-111 as well as multiple pre-clinical investigations of second generation candidates for other indications.
The Lecinoxoid platform is a family of small molecules that harnesses the ability of naturally occurring oxidized phospholipids to inhibit immune-inflammatory responses.